Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Subcutaneous octreotide acetate Clear all
Terminated Phase 3 Interventional

Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly

NCT01295060
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Denver, Colorado • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 23, 2026, 3:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 23, 2026, 3:49 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 23, 2026, 3:49 AM EDT
Terminated Phase 4 Interventional

Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding

NCT02032784
View directory record Official record
Conditions
Adenoma
Interventions
octreotide, No Octreotide
Drug · Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 23, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

NCT00005906
View directory record Official record
Conditions
Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
Interventions
Octreotide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Sep 23, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04076462
View directory record Official record
Conditions
Acromegaly
Interventions
CAM2029 (octreotide subcutaneous depot), Matching placebo
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 23, 2026, 3:49 AM EDT
Completed Phase 3 Interventional

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT04125836
View directory record Official record
Conditions
Acromegaly
Interventions
CAM2029 (octreotide subcutaneous depot)
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 23, 2026, 3:49 AM EDT
Completed Phase 2 Interventional

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

NCT00250796
View directory record Official record
Conditions
Liver, Cancer
Interventions
Thalidomide, alpha interferon, Thalidomide, interferon, Octreotide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
2
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 23, 2026, 3:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

NCT02195635
View directory record Official record
Conditions
Drug Interactions
Interventions
Telotristat etiprate, Octreotide acetate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2016 · Synced Sep 23, 2026, 3:49 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
CAM2029, Octreotide LAR, Lanreotide ATG
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 23, 2026, 3:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers

NCT03031535
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Intranasal octreotide acetate, Subcutaneous octreotide acetate, Growth hormone-releasing hormone, Arginine hydrochloride
Drug · Diagnostic Test
Lead sponsor
Dauntless Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 23, 2026, 3:49 AM EDT
Completed Phase 2 Interventional

Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

NCT03967249
View directory record Official record
Conditions
Acromegaly
Interventions
IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL)
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Birmingham, Alabama • Evanston, Illinois • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 23, 2026, 3:49 AM EDT
Terminated Not applicable Interventional Results available

Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)

NCT00399893
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Octreotide, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
5 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 23, 2026, 3:49 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

NCT03289741
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Octreotide, LAR Lanreotide, Questionnaires
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 23, 2026, 3:49 AM EDT
Terminated Phase 2 Interventional Results available

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

NCT06865677
View directory record Official record
Conditions
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
Interventions
Sacituzumab Govitecan, EKG, Brain MRI, CT scans, Tumor biopsy, Loperamide, Octreotide, Diphenoxylate/Atropine, Antiemetics
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 23, 2026, 3:49 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

NCT05281328
View directory record Official record
Conditions
Polycystic Liver Disease
Interventions
CAM2029, Placebo
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Rochester, Minnesota • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 23, 2026, 3:49 AM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

NCT00765323
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide Implant, Sandostatin LAR Depot
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Palo Alto, California • Denver, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 23, 2026, 3:49 AM EDT
Completed Phase 1 Interventional

Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

NCT03103009
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia
Interventions
Pasireotide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 23, 2026, 3:49 AM EDT